Key result
Targeted drug delivery systems, including nanomedicines, offer promising strategies for the precise treatment of atherosclerosis by localizing to plaques and minimizing systemic side effects.
Why the study?
Atherosclerosis progression is often covert, driving the need for early biomarkers and targeted therapeutic strategies that address specific disease processes.
Targeted drug delivery systems offer significant potential for improving drug stability and enabling personalized treatment for atherosclerosis by directly delivering drugs to plaque areas and minimizing impact on normal vascular tissues.
Should not yet change practice in atherosclerosis; leaves open the need for prospective trials to validate targeted delivery.
Atherosclerosis is a complex cardiovascular disease driven by multiple factors, including aging, inflammation, oxidative stress, and plaque rupture. The progression of this disease is often covert, emphasizing the need for early biomarkers and effective intervention measures. In recent years, advancements in therapeutic strategies have highlighted the potential of targeting specific processes in atherosclerosis, such as plaque localization, macrophage activity, and key enzymes. Based on this, this review discusses the potential role of targeted drugs in the treatment of atherosclerosis. It also focuses on their clinical efficacy in anti-atherosclerosis treatment and their ability to provide more precise therapeutic approaches. The findings underscore that future research can concentrate on exploring newer drug delivery systems and biomarkers to further refine clinical treatment strategies and enhance the long-term dynamic management of atherosclerosis. 1. Forming mechanisms of atherogenesis. 2. Impact of nanomedicines on atherosclerotic cancer patients: a systematic review. 3. Protective potential of immunity against atherosclerotic targets: a case-control study. 4. G3BP2 peptide immunization against atherosclerosis: a randomized controlled trial.
No takes yet. Share an insight, caveat, or question.
Tu et al. (2025) conducted a review in Atherosclerosis. Targeted drug delivery systems vs. Traditional therapies was evaluated. Targeted drug delivery systems, including nanomedicines, offer promising strategies for the precise treatment of atherosclerosis by localizing to plaques and minimizing systemic side effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: